Results 81 to 90 of about 54,594 (319)

rWTC‐MBTA Vaccine, Alone and Enhanced with Anti‐PD1, Elicits Immune Responses against CNS and Peripheral B‐Cell Lymphoma

Advanced Science, EarlyView.
An autologous whole‐tumor‐cell vaccine (rWTC‐MBTA) is evaluated in murine CNS lymphoma. Subcutaneous vaccination activates dendritic cells, broadens T‐cell priming, and drives lymphocyte trafficking to brain tumors, producing durable tumor control. Longitudinal bioluminescence and adoptive‐transfer assays verify CNS engagement. Combination with anti‐PD‐
Yaping Zhang, Juan Ye, Mitchell Sun, Samik Chakraborty, Alex Valenzuela, Shuran Chen, Qingfeng Xue, Wenyu Shi, Karel Pacak, Herui Wang, Zhengping Zhuang   +10 more
wiley   +1 more source

Surface‐Associated Proteins on Extracellular Vesicles Remodel the Tumor Microenvironment by Potentiating TGF‐β Signaling in a Contact‐Dependent Manner

Advanced Science, EarlyView.
Extracellular vesicles (EVs) released from TGF‐β‐activated CAFs are enriched with ECM proteins such as TSG6 and THBS1, which facilitate their binding to recipient cell membranes. This EV–cell interaction promotes the clustering of CD44 and TGF‐β receptors on the target cell surface, thereby potentiating TGF‐β signaling activity. This study highlights a
Chao Li, Agustin Enciso‐Martinez, Lizhe Zhu, Sarah A. Rotman, Peter A. van Veelen, Roman I. Koning, Hailiang Mei, Peter ten Dijke   +7 more
wiley   +1 more source

CD98 regulates the phosphorylation of HER2 and a bispecific anti‐HER2/CD98 antibody inhibits the growth signal of human breast cancer cells [PDF]

, 2023
Akitaka Yamasaki, Kumiko Maruyama‐Takahashi, Kento Nishida, Shogo Okazaki, Kouki Okita, Yasutoshi Akiyama, Hideaki Suzuki, Yuichi Endo, Kazue Masuko, Takashi Masuko, Yoshihisa Tomioka   +10 more
openalex   +1 more source

Ir(III) Complexes Convert Cold to Hot Tumors via Ferroptosis/Necroptosis‐Driven Immunogenic Cell Death and Photosensitized CD47 Downregulation

Advanced Science, EarlyView.
Red‐light‐activated Ir1 overcomes hypoxia tolerance and adapts to the immunosuppressive tumor microenvironment, converting immunologically cold tumors into inflamed hot microenvironments. This conversion is driven by synergistic induction of immunogenic cell death through coordinated ferroptosis‐necroptosis pathways and spatiotemporally controlled ...
Long‐Bo Yu, Peng Wang, Qing‐Hua Shen, Qi‐Xin Guan, Zhi‐Yuan Li, Ying‐Ying Han, Xin‐Yi Zhang, Qing‐Yuan Hu, Cai‐Ping Tan   +8 more
wiley   +1 more source

Comparison of CAR T-cell vs. bispecific antibody as third- or later-line large B-cell lymphoma therapy: A Meta-analysis.

Blood
This meta-analysis evaluates the efficacy and safety of chimeric antigen receptor (CAR) T-cell therapy and bispecific antibodies for relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL).
Jinchul Kim, Jinhyun Cho, Moon-Hee Lee, S. Yoon, Won Seog Kim, S. Kim   +5 more
semanticscholar   +1 more source

CD47xCD19 bispecific antibody triggers recruitment and activation of innate immune effector cells in a B-cell lymphoma xenograft model [PDF]

, 2022
Xavier Chauchet, Laura Cons, Laurence Chatel, Bruno Daubeuf, Gérard Didelot, Valéry Moine, Didier Chollet, Pauline Malinge, Guillemette Pontini, Krzysztof Masternak, Walter Ferlin, Vanessa Buatois, Limin Shang   +12 more
openalex   +1 more source

Bispecific Antibody-Functionalized Upconversion Nanoprobe [PDF]

Analytical Chemistry, 2018
Upconversion nanoparticles (UCNPs) are new optical probes for biological applications. For specific biomolecular recognition to be realized for diagnosis and imaging, the key lies in developing a stable and easy-to-use bioconjugation method for antibody modification.
Hao He, Christopher B. Howard, Yinghui Chen, Shihui Wen, Gungun Lin, Jiajia Zhou, Kristofer J. Thurecht, Dayong Jin   +7 more
openaire   +3 more sources

cDC1 Subtype‐Specific In Vivo Targeting of Liposomes

Advanced Science, EarlyView.
Dendritic cells, particularly the cDC1 subtype, offer a promising target for drug delivery via liposomes due to their pivotal role in immune regulation, allowing for amplified therapeutic responses. Herein, we show an integration of physicochemical characterization and cell experiments to achieve effective in vivo cDC1 targeting through anti‐CLEC9A ...
Maximilian Schaaf, Michael Fichter, Lin Jian, Felicia Schön, Carina Jung, Paul Schneider, Kai Speth, Ana Mateos‐Maroto, Volker Mailänder, Kaloian Koynov, Svenja Morsbach, Katharina Landfester   +11 more
wiley   +1 more source

The Bispecific Tumor Antigen-Conditional 4–1BB x 5T4 Agonist, ALG.APV-527, Mediates Strong T-Cell Activation and Potent Antitumor Activity in Preclinical Studies [PDF]

, 2022
Michelle H. Nelson, Sara Fritzell, Robert E. Miller, Doreen Werchau, Danielle Van Citters, Anneli Nilsson, Lynda Misher, Lill Ljung, Robert Bader, Adnan Deronic, Allison G. Chunyk, Lena Schultz, Laura A. Varas, Nadia Rose, M. Håkansson, Jane A. Gross, Christina Furebring, Peter Pavlik, Anette Sundstedt, Niina Veitonmäki, Hilario J. Ramos, Anna Säll, Anna Dahlman, David Bienvenue, Laura von Schantz, Catherine J. McMahan, Maria Askmyr, Gabriela Hernández‐Hoyos, Peter Ellmark   +28 more
openalex   +1 more source

Bispecific antibodies in cancer immunotherapy [PDF]

Human Vaccines & Immunotherapeutics, 2016
Cancer immunotherapy has recently generated much excitement after the continuing success of the immunomodulating anti-CTLA-4 and anti-PD-1 antibodies against various types of cancers. Aside from these immunomodulating antibodies, bispecific antibodies, chimeric antigen receptor T cells, and other technologies are being actively studied.
Siqi, Chen, Jing, Li, Qing, Li, Zhong, Wang   +3 more
openaire   +2 more sources